Sun Pharma's IL-23 inhibitor tildrakizumab gains a psoriatic arthritis indication; the announcement cited no phase 3 efficacy figures.
Feature|Articles|December 10, 2023
- Pharmaceutical Executive: December 2023
- Volume 43
- Issue 12
Pharmaceutical Executive: December 2023 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive December 2023 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 3 years ago
Finding that Sparkalmost 3 years ago
Remote Reliance: The Rise of Oncology Home Carealmost 3 years ago
It’s Always Important to Remember: Leaders Make Mistakesalmost 3 years ago
Will Calendar Change Bring an End to Run of Volatility in Biotech?almost 3 years ago
FDA, Industry Face Challenges in the Year Aheadalmost 3 years ago
Navigating the Future: Key Market Access Trends to Watch in ’24almost 3 years ago
Reflecting on 2023Advertisement
Related to this article
Brox.AI's co-founder and CEO on why telling an AI to pretend to be a doctor isn’t the same as cloning one — and why that distinction matters for pharma.
Shionogi’s Dr. Draica on why mild COVID-19 still matters, how XOCOVA blocks replication before symptoms, and why prevention beats treatment.
Earlier pediatric planning, innovative trial design, and closer collaboration among regulators, industry, and families are needed to close the persistent gap between the evidence available for adult and pediatric treatments.
BioMarin licenses long-acting Fabry enzyme replacement therapy HM15421/GC1134A, while Ferring agrees to acquire fertility biotech Gameto.
As AI accelerates drug discovery, the industry’s next challenge is building a connected, standards-based data infrastructure capable of supporting it through clinical development.
Shionogi’s Dr. Draica on why mild COVID-19 can worsen chronic conditions for up to a year — and why prevention matters more than hospitalization data suggests.
Brock.AI’s Hamish Brocklebank on recruiting 8% of all US pancreatic cancer prescribers — paying $2,000 an hour, offering equity, and triple opt-in consent.
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: BioMarin Licenses Long-Acting Fabry Enzyme Therapy for $70 Million Upfront, Ferring to Acquire Fertility Biotech Gameto in Deal Worth Up to $1.38 Billion
2
Bristol Myers Squibb Discloses Patient Death in CAR-T Multiple Sclerosis Trial
3
Rebuilding Clinical Data Workflows for the AI Era
4
How Preventative Medications May Impact the Lingering Impact of COVID-19
5